ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 309

Periarticular Tibial Knee Bone Mineral Density Is Associated with Knee Symptoms

Grace H. Lo1, Jeffrey B. Driban2, Michael P. LaValley3, Michael T. Strayhorn4, Lori Lyn Price5, Charles Eaton6 and Timothy E. McAlindon7, 1Immunology, Allergy, Rheumatology, Baylor College of Medicine, Houston, TX, 2Rheumatology, Tufts Medical Center, Boston, MA, 3Biostatistics, Boston University School of Public Health, Boston, MA, 4VA HSR&D Center for Innovations in Quality, Effectiveness and Safety; Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, 5Clinical Care Research, Tufts Medical Center, Boston, MA, 6Brown University, Providence, RI, 7Division of Rheumatology, Tufts Medical Center, Boston, MA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: DXA, OA and osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Osteoarthritis – Clinical Aspects - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Periarticular Tibial Knee Bone Mineral Density is Associated with Knee Symptoms Lo GH, Driban JB, LaValley M, Strayhorn M, Price LL, Eaton CB, McAlindon TE

Background/Purpose: Relative local knee periarticular bone mineral density (paBMD) as measured by dual x-ray absorptiometry (DXA) has been associated with features of radiographic knee osteoarthritis (OA).   We postulated that this measure is associated with knee pain and measures of quality of life. To address this question, we evaluated the association of paBMD with pain and quality of life. 

Methods: We performed a cross-sectional study of a subgroup of the incidence subcohort of the Osteoarthritis Initiative (OAI) who had knee DXA scans from the 72-month visit.  We evaluated the right knee using identical GE Lunar Prodigy scanners, generating knee medial:lateral paBMD ratios focused on the tibial plateau.  Frequency of knee pain was assessed using the 72-month visit question, “In the past 12 months, have you had pain, aching or stiffness in or around your knee on most days for at least one month?”  The Knee injury and Osteoarthritis Outcome Score quality of life (QOL) assessments were also evaluated as outcomes – each item was dichotomized with a high score considered a symptomatic outcome. We performed logistic regression with a predictor of medial:lateral paBMD groups based on biologic cut points (1) low paBMD Ratio group with scores < 1.02, (2) neutral group (referent) with scores ≥ 1.02 and < 1.17, (3) high group with scores ≥ 1.17 and < 1.24 and (4) very high group with scores ≥ 1.24.  Analyses were adjusted for age, sex, and BMI.

Results: 985 participants, 51% female, were included with a mean age of 65.4 (8.4) years and BMI of 28.1 (4.9) kg/m2.  The very high paBMD Ratio group had more pain compared to the neutral group (Table 1). 

Table 1.  Medial:Lateral paBMD Ratio Groups as predictors for frequent knee pain.
Medial:Lateral paBMD Ratio groups Prevalence of Frequent Knee Pain Unadjusted OR Adjusted OR*
Low (<1.02) 41/193 (21%) 1.0 (0.7 – 1.6) 1.0 (0.7 – 1.6)
Neutral (≥1.02, <1,17) 107/517 (21%) Referent Referent
High (≥1.17, <1,24) 32/142 (23%) 1.1 (0.7 – 1.7) 1.1 (0.7 – 1.7)
Very High (≥1.24) 33/106 (31%) 1.7 (1.1 – 2.8) 1.7 (1.1 – 2.8)
Prevalence of QoL Q1 How Often Aware of Knee Problems
Low (<1.02) 96/193 (50%) 1.4 (1.0 – 1.9) 1.5 (1.4 – 2.1)
Neutral (≥1.02, <1,17) 217/515 (42%) Referent Referent
High (≥1.17, <1,24) 72/140 (51%) 1.5 (1.0 – 2.1) 1.4 (1.0 – 2.1)
Very High (≥1.24) 57/106 (54%) 1.6 (1.1 – 2.4) 1.7 (1.1 – 2.6)
Prevalence of QoL Q2 How Often Modified Lifestyle
Low (<1.02) 32/194 (17%) 1.0 (0.6 – 1.5) 1.0 (0.6 – 1.6)
Neutral (≥1.02, <1,17) 88/516 (17%) Referent Referent
High (≥1.17, <1,24) 41/141 (29%) 2.0 (1.3 – 3.1) 2.0 (1.3 – 3.1)
Very High (≥1.24) 23/106 (22%) 1.4 (0.8 – 2.2) 1.3 (0.8 – 2.3)
Prevalence of QoL Q3 How Often Troubled by Lack of Confidence in Knee
Low (<1.02) 26/194 (13%) 1.3 (0.8 – 2.1) 1.4 (0.8 – 2.3)
Neutral (≥1.02, <1,17) 55/515 (11%) Referent Referent
High (≥1.17, <1,24) 23/141 (16%) 1.6 (1.0 – 2.8) 1.5 (0.9 – 2.6)
Very High (≥1.24) 17/106 (16%) 1.6 (0.9 – 2.9) 1.4 (0.8 – 2.6)
Prevalence of QoL Q4 How Much Difficulty Have with Knee?
Low (<1.02) 31/194 (16%) 1.3 (0.8 – 2.1) 1.4 (0.9 – 3.0)
Neutral (≥1.02, <1,17) 65/515 (13%) Referent Referent
High (≥1.17, <1,24) 28/141 (20%) 1.7 (1.1 – 2.8) 1.7 (1.0 – 2.8)
Very High (≥1.24) 22/106 (21%) 1.8 (1.1 – 3.1) 1.7 (1.0 – 3.0)
*Adjusted for Age, sex, and bmi.

Conclusion: Relative local paBMD is associated with contemporaneous knee pain and some quality of life assessments.  These findings may suggest that changes within the local bone have a clinically relevant influence on knee pain.  Modification of the medial:lateral paBMD Ratio may improve knee pain and assist in identifying new targets of therapy.   


Disclosure: G. H. Lo, NIH, 2; J. B. Driban, None; M. P. LaValley, NIH, 2; M. T. Strayhorn, None; L. L. Price, NIH, 2; C. Eaton, NIH, 2; T. E. McAlindon, NIH, 2.

To cite this abstract in AMA style:

Lo GH, Driban JB, LaValley MP, Strayhorn MT, Price LL, Eaton C, McAlindon TE. Periarticular Tibial Knee Bone Mineral Density Is Associated with Knee Symptoms [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/periarticular-tibial-knee-bone-mineral-density-is-associated-with-knee-symptoms/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/periarticular-tibial-knee-bone-mineral-density-is-associated-with-knee-symptoms/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology